Purpose: To evaluate the effectiveness of zonisamide (ZNS) as monotherapy in children with newly diagnosed epilepsy. Methods: This randomized, multicenter trial included a 2-4-week titration and a 24-week maintenance phase after randomization to low-(3-4 mg/kg/day) or high-(6-8 mg/kg/day) dose groups as target maintenance dosages. The primary outcome measure was the seizure-free rate over 6 months, while a secondary measure was the change in cognition and behavior from screening to the end of the maintenance phase. Results: Out of 125 patients enrolled, 90 (49 low-dose and 41 high-dose) completed the study. Forty-one patients (63.1%) in the low-dose group and 34(57.6%) in the high-dose group achieved 6 months' freedom from seizures (p = 0.66). After treatment, the picture arrangement subtest improved in the low-dose group (p = 0.047) while the vocabulary subtest worsened in the high-dose group (p = 0.020). Comparing between the two groups, the vocabulary subtest in the high-dose group was significantly worse than that in the low-dose group (p = 0.002). Social competence, somatic complaints, depression/anxiety and delinquent and aggressive behavior in the low-dose group were significantly improved (p < 0.05). Moreover, total social competence, somatic complaints, delinquent behavior, externalizing, and total behavior problems were significantly more improved in the low-dose group than the high-dose group (p < 0.05). Conclusions: ZNS is an effective monotherapy for newly diagnosed childhood epilepsy. Lower doses of ZNS have a similar efficacy and more beneficial neurocognitive effects compared to higher doses. When prescribing higher doses of ZNS, one must be aware of the possible manifestation of problems associated with language development, such as those affecting vocabulary acquisition. © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Eun, S. H., Kim, H. D., Eun, B. L., Lee, I. K., Chung, H. J., Kim, J. S., … Moon, H. K. (2011). Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure, 20(7), 558–563. https://doi.org/10.1016/j.seizure.2011.04.005